Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.

INTRODUCTION: Mast cells participate in atherogenesis by releasing cytokines to induce vascular cell protease expression. Tryptase is expressed highly in human atherosclerotic lesions and the inhibition of tryptase activity hampers its capacity to maintain cholesterol inside macrophague foam cells....

Full description

Bibliographic Details
Main Authors: María Moreno, Josep Puig, Marta Serrano, José María Moreno-Navarrete, Francisco Ortega, Wifredo Ricart, Jose Manuel Fernandez-Real
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4022630?pdf=render
id doaj-aafd4a76bc344ed98a2f9453bb34ee85
record_format Article
spelling doaj-aafd4a76bc344ed98a2f9453bb34ee852020-11-25T01:34:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9701410.1371/journal.pone.0097014Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.María MorenoJosep PuigMarta SerranoJosé María Moreno-NavarreteFrancisco OrtegaWifredo RicartJose Manuel Fernandez-RealINTRODUCTION: Mast cells participate in atherogenesis by releasing cytokines to induce vascular cell protease expression. Tryptase is expressed highly in human atherosclerotic lesions and the inhibition of tryptase activity hampers its capacity to maintain cholesterol inside macrophague foam cells. We aimed to investigate the association between circulating tryptase levels and subclinical atherosclerosis through estimation of carotid intima-media thickness (c-IMT) as surrogate marker for increased cardiovascular risk in obese and non-obese subjects. METHODS: Circulating tryptase levels (ELISA) and metabolic parameters were analyzed in 228 subjects. Atherosclerosis (c-IMT>0.9 mm) was evaluated ultrasonographically. RESULTS: Significant positive associations were evident between circulating tryptase levels and BMI, fat mass, glycated haemoglobin, fasting insulin, HOMAIR, fasting triglycerides and ultrasensitive PCR (p<0.05 from linear-trend ANOVA). The positive association between tryptase levels and insulin resistance parameters, suggested a glucose homeostasis impairment in individuals with higher tryptase levels. The negative association between tryptase levels and HDL-cholesterol supports the proatherogenic role of this protease (p<0.0001). Circulating tryptase levels were strongly associated with c-IMT measurements (p<0.0001 from linear-trend ANOVA), and were higher in subjects with presence of carotid plaque (p<0.0001). Tryptase levels (beta = 0.015, p = 0.001) contributed independently to subclinical atherosclerosis variance after controlling for cardiovascular risk factors (BMI, blood pressure, LDL-cholesterol). CONCLUSIONS: Circulating tryptase level is associated to obesity related parameters and has a close relation with various metabolic risk factors. Moreover, serum tryptase level was independently associated with c-IMT, suggesting its potential use as a surrogate marker for subclinical atherosclerosis in obese subjects.http://europepmc.org/articles/PMC4022630?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author María Moreno
Josep Puig
Marta Serrano
José María Moreno-Navarrete
Francisco Ortega
Wifredo Ricart
Jose Manuel Fernandez-Real
spellingShingle María Moreno
Josep Puig
Marta Serrano
José María Moreno-Navarrete
Francisco Ortega
Wifredo Ricart
Jose Manuel Fernandez-Real
Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
PLoS ONE
author_facet María Moreno
Josep Puig
Marta Serrano
José María Moreno-Navarrete
Francisco Ortega
Wifredo Ricart
Jose Manuel Fernandez-Real
author_sort María Moreno
title Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
title_short Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
title_full Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
title_fullStr Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
title_full_unstemmed Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
title_sort circulating tryptase as a marker for subclinical atherosclerosis in obese subjects.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description INTRODUCTION: Mast cells participate in atherogenesis by releasing cytokines to induce vascular cell protease expression. Tryptase is expressed highly in human atherosclerotic lesions and the inhibition of tryptase activity hampers its capacity to maintain cholesterol inside macrophague foam cells. We aimed to investigate the association between circulating tryptase levels and subclinical atherosclerosis through estimation of carotid intima-media thickness (c-IMT) as surrogate marker for increased cardiovascular risk in obese and non-obese subjects. METHODS: Circulating tryptase levels (ELISA) and metabolic parameters were analyzed in 228 subjects. Atherosclerosis (c-IMT>0.9 mm) was evaluated ultrasonographically. RESULTS: Significant positive associations were evident between circulating tryptase levels and BMI, fat mass, glycated haemoglobin, fasting insulin, HOMAIR, fasting triglycerides and ultrasensitive PCR (p<0.05 from linear-trend ANOVA). The positive association between tryptase levels and insulin resistance parameters, suggested a glucose homeostasis impairment in individuals with higher tryptase levels. The negative association between tryptase levels and HDL-cholesterol supports the proatherogenic role of this protease (p<0.0001). Circulating tryptase levels were strongly associated with c-IMT measurements (p<0.0001 from linear-trend ANOVA), and were higher in subjects with presence of carotid plaque (p<0.0001). Tryptase levels (beta = 0.015, p = 0.001) contributed independently to subclinical atherosclerosis variance after controlling for cardiovascular risk factors (BMI, blood pressure, LDL-cholesterol). CONCLUSIONS: Circulating tryptase level is associated to obesity related parameters and has a close relation with various metabolic risk factors. Moreover, serum tryptase level was independently associated with c-IMT, suggesting its potential use as a surrogate marker for subclinical atherosclerosis in obese subjects.
url http://europepmc.org/articles/PMC4022630?pdf=render
work_keys_str_mv AT mariamoreno circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
AT joseppuig circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
AT martaserrano circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
AT josemariamorenonavarrete circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
AT franciscoortega circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
AT wifredoricart circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
AT josemanuelfernandezreal circulatingtryptaseasamarkerforsubclinicalatherosclerosisinobesesubjects
_version_ 1725070915503390720